Timothy P Cripe MD, PhD


Timothy P Cripe MD, PhD
ProfessorCollege of Medicinetimothy.cripe@nationwidechildrens.org
700 Childrens Dr Columbus OH 43205
Phone:614-722-3552Fax: 614-722-3699
  • Viral Oncology

General Research Interest

Oncolytic virotherapy, targeted small molecule inhibitors, non-CNS solid tumors in children

Research Description

My laboratory is interested in developing and studying targeted therapeutics for non-CNS solid tumors in children, particularly sarcomas and neuroblastoma. Our efforts are primarily focused on the development of oncolytic virotherapy as well as small molecule targeted inhibitors. Active projects include studies of the mechanism and enhancement of tumor-selective virus delivery for metastatic disease, the role and manipulation of regulatory T cells in the antiviral and antitumor immune response, the utility of incorporating therapeutic transgenes to modify the tumor microenvironment, the effect of small molecule inhibitors combined with oncolytic virus infection, and the effect of oncolytic viruses on cancer stem cells.  

Transinstitutional Work

We have ongoing collaborations with Drs E.A. Chiocca and B. Kaur in the OSUCCC Department of Neurosurgery in the area of oncolytic virotherapy, with Dr. N. Ratner in the Division of Experimental Hematology & Cancer Biology at Cincinnati Children’s Research Foundation in the area of neurofibromatosis and malignant peripheral nerve sheath tumors, and with Dr. S. Wells in the Division of Hematology/Oncology at Cincinnati Children’s Research Foundation in the area of human papillomavirus-associated tumorigenesis.

Current Publications

  • Ratner NMAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.Oncogene 2/10/2014
  • Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller JPilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.Pediatr Blood Cancer 60(9) 1447-51 9/1/2013
  • Wang PY, Currier MA, Hansford L, Kaplan D, Chiocca EA, Uchida H, Goins WF, Cohen JB, Glorioso JC, van Kuppevelt TH, Mo X, Cripe TP, Chiocca , chiocca Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV.Gene Ther 20(7) 761-9 7/1/2013
  • Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TPVEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.Mol Ther 21(5) 1014-23 5/1/2013
  • Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner NEGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.Oncogene in press 1/14/2013
  • Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Dudley AH, Niwa-Kawakita M, Page GP, Giovannini M, Aronow B, Cripe TP, Ratner NMEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.J Clin Invest 123(1) 340-7 1/2/2013
  • Patmore DM, Welch S, Fulkerson PC, Wu J, Choi K, Eaves D, Kordich JJ, Collins MH, Cripe TP, Ratner NIn vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1.Cancer Res 72(20) 5317-27 10/15/2012
  • Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow B, Perentesis J, Serra E, Cripe T, Miller SC, Ratner NRas-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.Clin Cancer Res 18(18) 5020-30 9/15/2012
  • Cripe TPDiffering approaches to experimental therapeutics: are we a world apart?Mol Ther 20(9) 1649-50 9/1/2012
  • Kaur B, Chiocca EA, Cripe TPOncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.Curr Pharm Biotechnol 13(9) 1842-51 7/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu